Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated:  12/31/1969
mi
from
Villejuif,
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Enrolling
Updated: 12/31/1969
mi
from
Villejuif,
Click here to add this to my saved trials
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients With Advanced Solid Tumors, With Dose-expansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breast Cancer (BC) Patients.
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center SC - BYL719Z2102
mi
from
New York, NY
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients With Advanced Solid Tumors, With Dose-expansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breast Cancer (BC) Patients.
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center SC - BYL719Z2102
mi
from
New York, NY
Click here to add this to my saved trials
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients With Advanced Solid Tumors, With Dose-expansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breast Cancer (BC) Patients.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Bordeaux Cedex,
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients With Advanced Solid Tumors, With Dose-expansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breast Cancer (BC) Patients.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Bordeaux Cedex,
Click here to add this to my saved trials
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients With Advanced Solid Tumors, With Dose-expansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breast Cancer (BC) Patients.
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients With Advanced Solid Tumors, With Dose-expansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breast Cancer (BC) Patients.
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Barrow Neurological Insitute St. Joseph's Hospital
mi
from
Phoenix, AZ
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Barrow Neurological Insitute St. Joseph's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Heidelberg,
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Heidelberg,
Click here to add this to my saved trials
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Smilow Cancer Center at Yale New Haven Hospital
mi
from
New Haven, CT
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Smilow Cancer Center at Yale New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
Status: Enrolling
Updated:  12/31/1969
University of Michigan Hospital
mi
from
Ann Arbor, MI
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
Status: Enrolling
Updated: 12/31/1969
University of Michigan Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center International Plaza
mi
from
Tampa, FL
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center International Plaza
mi
from
Tampa, FL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
A Phase 2 Study Using Stereotactic Ablative Radiation Therapy and Ipilimumab in Patients With Oligometastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
A Phase 2 Study Using Stereotactic Ablative Radiation Therapy and Ipilimumab in Patients With Oligometastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Riley Hospital for Children
mi
from
Indianapolis, IN
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Colorado
mi
from
Aurora, CO
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Childrens National Medical Center
mi
from
Washington,
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center at Parnassus
mi
from
San Francisco, CA
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center at Parnassus
mi
from
San Francisco, CA
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center-Mission Bay
mi
from
San Francisco, CA
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center-Mission Bay
mi
from
San Francisco, CA
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials